Satoshi Yokoyama
Overview
Explore the profile of Satoshi Yokoyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahara Y, Kashiwagi Y, Tokuda T, Yoshimoto J, Sakai Y, Yamashita A, et al.
Neural Netw
. 2025 Mar;
187:107335.
PMID: 40068496
Objective classification biomarkers that are developed using resting-state functional magnetic resonance imaging (rs-fMRI) data are expected to contribute to more effective treatment for psychiatric disorders. Unfortunately, no widely accepted biomarkers...
2.
Nakano W, Yokoyama S, Sato H
Cureus
. 2025 Jan;
16(12):e75351.
PMID: 39781147
Background and aim Subthreshold depression is a potential risk factor for major depressive disorder. Although the neurobiological mechanism underlying major depressive disorder is well-established, the mechanism underlying subthreshold depression has...
3.
Yokoyama S, Nakagawa C, Uno T, Hosomi K
Biol Pharm Bull
. 2024 Nov;
47(11):1851-1857.
PMID: 39522979
Hyperuricemia is defined as high uric acid levels within the bloodstream and is commonly associated with gout, type 2 diabetes mellitus, and kidney disease. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are...
4.
Nakagawa C, Ota R, Hirata A, Yokoyama S, Uno T, Hosomi K
Biol Pharm Bull
. 2024 Oct;
47(10):1759-1767.
PMID: 39477469
Rheumatoid arthritis (RA) patients receiving biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) often experience treatment changes due to inefficacy or adverse events. The purpose of this study was to...
5.
Uno T, Hosomi K, Yokoyama S
Sci Rep
. 2024 Oct;
14(1):25943.
PMID: 39472632
Tolvaptan-associated hepatic disorder is a rare, but lethal adverse event; however, the precise risk and time of onset remain unclear. This study aimed to characterize the severity, time‑to‑onset, and outcomes...
6.
Nakagawa J, Ishido K, Kimura N, Nagase H, Wakasa Y, Yokoyama S, et al.
J Pharm Health Care Sci
. 2024 Oct;
10(1):66.
PMID: 39468637
Background: Edoxaban, the only factor Xa inhibitor with active metabolites, is metabolized by carboxylesterase-1 to its main active metabolite, M-4, which is a substrate of organic anion transporting polypeptide 1B1...
7.
Nakamura A, Kimura Y, Tanaka Y, Tsuchimoto D, Naruse A, Kanematsu T, et al.
Eur J Haematol
. 2024 Oct;
114(2):267-275.
PMID: 39439083
Although lenalidomide is an essential treatment for multiple myeloma (MM), skin rashes are a common adverse event. This retrospective study aimed to examine the association between skin rash development during...
8.
Takagaki K, Yokoyama S
Behav Sci (Basel)
. 2024 Aug;
14(8).
PMID: 39199109
Subthreshold depression is a risk factor for depression among university students. Positive environmental reinforcement is a significant mediator of avoidance and depression in healthy university students. However, this relationship is...
9.
Yokoyama S, Adachi T, Yoshino A
Sci Rep
. 2024 Jul;
14(1):17176.
PMID: 39060508
Pain experiences are often complex with catastrophic cognitions, emotions, and behaviors. Cognitive behavioral therapists share the work of unraveling these complex experiences with their patients. However, the change process underlying...
10.
Yokoyama S, Shikano A, Chiba H, Murakami T, Kawamorita T, Murayama T, et al.
PEC Innov
. 2024 Jul;
4:100302.
PMID: 38966314
Objective: Machine learning models were employed to discern patients' impressions from the therapists' facial expressions during a virtual online video counselling session. Methods: Eight therapists simulated an online video counselling...